Resonance HealthASX:RHT +4.55% Net Margin % is 18.38% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Resonance Health ranks better than 63.17% on this metric.
The historical rank and industry rank for Resonance Health's Net Margin % or its related term are showing as below:
ASX:RHT'
s Net Margin % Range Over the Past 10 Years
Min: -29.83 Med: -13.65 Max: 35.03
Current: 5.56
ASX:RHT's Net Margin % is ranked better than 63.17% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs ASX:RHT: 5.56
Resonance Health (ASX:RHT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Resonance Health Net Margin % Related Terms
Resonance Health Net Margin % Historical Data
* Premium members only.
The historical data trend for Resonance Health's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: Net Margin % Comparison
For the Health Information Services subindustry, Resonance Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Net Margin % distribution charts can be found below:
* The bar in red indicates where Resonance Health's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Net Margin % of 18.38% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #246 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 36.8%.
Is Resonance Health's Net Margin % too high?
Resonance Health's current Net Margin % is 18.38%. The Healthcare Providers & Services industry median Net Margin % is 2.89. Resonance Health's value of 18.38% is 537.1% above this industry median. Based on the distribution chart, Resonance Health ranks #246 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's Net Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #246 out of 668 companies for Net Margin %. This puts Resonance Health in the upper half of its industry. The industry median Net Margin % is 2.89. Resonance Health's value of 18.38% is 537.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Net Margin % of 18.38% is 537.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Net Margin % is 18.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current Net Margin % is 18.38% and 537.1% above the Healthcare Providers & Services industry median of 2.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Net Margin % is 18.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 